nodes	percent_of_prediction	percent_of_DWPC	metapath
Milnacipran—Erythema multiforme—Dactinomycin—muscle cancer	0.0075	0.0075	CcSEcCtD
Milnacipran—Flushing—Dactinomycin—muscle cancer	0.00736	0.00736	CcSEcCtD
Milnacipran—Chills—Dactinomycin—muscle cancer	0.00712	0.00712	CcSEcCtD
Milnacipran—Hypoaesthesia—Vincristine—muscle cancer	0.00705	0.00705	CcSEcCtD
Milnacipran—Hallucination—Vincristine—muscle cancer	0.00705	0.00705	CcSEcCtD
Milnacipran—Urinary tract disorder—Vincristine—muscle cancer	0.007	0.007	CcSEcCtD
Milnacipran—Connective tissue disorder—Vincristine—muscle cancer	0.00696	0.00696	CcSEcCtD
Milnacipran—Urethral disorder—Vincristine—muscle cancer	0.00695	0.00695	CcSEcCtD
Milnacipran—Delirium—Doxorubicin—muscle cancer	0.00689	0.00689	CcSEcCtD
Milnacipran—Neutropenia—Etoposide—muscle cancer	0.00671	0.00671	CcSEcCtD
Milnacipran—Cystitis noninfective—Methotrexate—muscle cancer	0.00669	0.00669	CcSEcCtD
Milnacipran—Cystitis—Methotrexate—muscle cancer	0.00661	0.00661	CcSEcCtD
Milnacipran—Cardiac disorder—Vincristine—muscle cancer	0.00658	0.00658	CcSEcCtD
Milnacipran—Ventricular extrasystoles—Doxorubicin—muscle cancer	0.00656	0.00656	CcSEcCtD
Milnacipran—Angiopathy—Vincristine—muscle cancer	0.00643	0.00643	CcSEcCtD
Milnacipran—Mediastinal disorder—Vincristine—muscle cancer	0.00639	0.00639	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.00634	0.00634	CcSEcCtD
Milnacipran—Mental disorder—Vincristine—muscle cancer	0.00621	0.00621	CcSEcCtD
Milnacipran—Bladder pain—Methotrexate—muscle cancer	0.00619	0.00619	CcSEcCtD
Milnacipran—Leukopenia—Dactinomycin—muscle cancer	0.00618	0.00618	CcSEcCtD
Milnacipran—Hepatobiliary disease—Etoposide—muscle cancer	0.00605	0.00605	CcSEcCtD
Milnacipran—Cystitis noninfective—Doxorubicin—muscle cancer	0.00579	0.00579	CcSEcCtD
Milnacipran—Cystitis—Doxorubicin—muscle cancer	0.00573	0.00573	CcSEcCtD
Milnacipran—Hypoaesthesia—Etoposide—muscle cancer	0.00571	0.00571	CcSEcCtD
Milnacipran—Urinary tract disorder—Etoposide—muscle cancer	0.00567	0.00567	CcSEcCtD
Milnacipran—Agitation—Vincristine—muscle cancer	0.00567	0.00567	CcSEcCtD
Milnacipran—Urethral disorder—Etoposide—muscle cancer	0.00563	0.00563	CcSEcCtD
Milnacipran—Infection—Dactinomycin—muscle cancer	0.0056	0.0056	CcSEcCtD
Milnacipran—Leukopenia—Vincristine—muscle cancer	0.00552	0.00552	CcSEcCtD
Milnacipran—Thrombocytopenia—Dactinomycin—muscle cancer	0.00552	0.00552	CcSEcCtD
Milnacipran—Dry eye—Doxorubicin—muscle cancer	0.00548	0.00548	CcSEcCtD
Milnacipran—Erythema multiforme—Etoposide—muscle cancer	0.00543	0.00543	CcSEcCtD
Milnacipran—Renal failure acute—Methotrexate—muscle cancer	0.00538	0.00538	CcSEcCtD
Milnacipran—Anorexia—Dactinomycin—muscle cancer	0.00537	0.00537	CcSEcCtD
Milnacipran—Eye disorder—Etoposide—muscle cancer	0.00536	0.00536	CcSEcCtD
Milnacipran—Bladder pain—Doxorubicin—muscle cancer	0.00536	0.00536	CcSEcCtD
Milnacipran—Convulsion—Vincristine—muscle cancer	0.00535	0.00535	CcSEcCtD
Milnacipran—Flushing—Etoposide—muscle cancer	0.00533	0.00533	CcSEcCtD
Milnacipran—Cardiac disorder—Etoposide—muscle cancer	0.00533	0.00533	CcSEcCtD
Milnacipran—Hypertension—Vincristine—muscle cancer	0.00533	0.00533	CcSEcCtD
Milnacipran—Angiopathy—Etoposide—muscle cancer	0.00521	0.00521	CcSEcCtD
Milnacipran—Mediastinal disorder—Etoposide—muscle cancer	0.00517	0.00517	CcSEcCtD
Milnacipran—Chills—Etoposide—muscle cancer	0.00515	0.00515	CcSEcCtD
Milnacipran—Infection—Vincristine—muscle cancer	0.005	0.005	CcSEcCtD
Milnacipran—Nervous system disorder—Vincristine—muscle cancer	0.00494	0.00494	CcSEcCtD
Milnacipran—Thrombocytopenia—Vincristine—muscle cancer	0.00493	0.00493	CcSEcCtD
Milnacipran—Decreased appetite—Dactinomycin—muscle cancer	0.0049	0.0049	CcSEcCtD
Milnacipran—Dysgeusia—Etoposide—muscle cancer	0.00489	0.00489	CcSEcCtD
Milnacipran—Hyperhidrosis—Vincristine—muscle cancer	0.00487	0.00487	CcSEcCtD
Milnacipran—Fatigue—Dactinomycin—muscle cancer	0.00486	0.00486	CcSEcCtD
Milnacipran—Anorexia—Vincristine—muscle cancer	0.0048	0.0048	CcSEcCtD
Milnacipran—Irritability—Methotrexate—muscle cancer	0.00474	0.00474	CcSEcCtD
Milnacipran—Hypotension—Vincristine—muscle cancer	0.0047	0.0047	CcSEcCtD
Milnacipran—Renal failure acute—Doxorubicin—muscle cancer	0.00466	0.00466	CcSEcCtD
Milnacipran—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00461	0.00461	CcSEcCtD
Milnacipran—Hot flush—Doxorubicin—muscle cancer	0.0046	0.0046	CcSEcCtD
Milnacipran—Liver function test abnormal—Methotrexate—muscle cancer	0.00459	0.00459	CcSEcCtD
Milnacipran—Menopausal symptoms—Doxorubicin—muscle cancer	0.00456	0.00456	CcSEcCtD
Milnacipran—Insomnia—Vincristine—muscle cancer	0.00455	0.00455	CcSEcCtD
Milnacipran—Paraesthesia—Vincristine—muscle cancer	0.00452	0.00452	CcSEcCtD
Milnacipran—Breast disorder—Methotrexate—muscle cancer	0.00449	0.00449	CcSEcCtD
Milnacipran—Leukopenia—Etoposide—muscle cancer	0.00447	0.00447	CcSEcCtD
Milnacipran—Abdominal pain—Dactinomycin—muscle cancer	0.00445	0.00445	CcSEcCtD
Milnacipran—Body temperature increased—Dactinomycin—muscle cancer	0.00445	0.00445	CcSEcCtD
Milnacipran—Loss of consciousness—Etoposide—muscle cancer	0.00439	0.00439	CcSEcCtD
Milnacipran—Decreased appetite—Vincristine—muscle cancer	0.00438	0.00438	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Vincristine—muscle cancer	0.00435	0.00435	CcSEcCtD
Milnacipran—Fatigue—Vincristine—muscle cancer	0.00434	0.00434	CcSEcCtD
Milnacipran—Convulsion—Etoposide—muscle cancer	0.00433	0.00433	CcSEcCtD
Milnacipran—Hyponatraemia—Doxorubicin—muscle cancer	0.00432	0.00432	CcSEcCtD
Milnacipran—Hypertension—Etoposide—muscle cancer	0.00431	0.00431	CcSEcCtD
Milnacipran—Constipation—Vincristine—muscle cancer	0.00431	0.00431	CcSEcCtD
Milnacipran—Chest pain—Etoposide—muscle cancer	0.00425	0.00425	CcSEcCtD
Milnacipran—Migraine—Doxorubicin—muscle cancer	0.00424	0.00424	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00423	0.00423	CcSEcCtD
Milnacipran—Hypersensitivity—Dactinomycin—muscle cancer	0.00415	0.00415	CcSEcCtD
Milnacipran—Gastrointestinal pain—Vincristine—muscle cancer	0.00412	0.00412	CcSEcCtD
Milnacipran—Infection—Etoposide—muscle cancer	0.00405	0.00405	CcSEcCtD
Milnacipran—Asthenia—Dactinomycin—muscle cancer	0.00404	0.00404	CcSEcCtD
Milnacipran—Dysuria—Methotrexate—muscle cancer	0.00402	0.00402	CcSEcCtD
Milnacipran—Neutropenia—Methotrexate—muscle cancer	0.00402	0.00402	CcSEcCtD
Milnacipran—Thrombocytopenia—Etoposide—muscle cancer	0.00399	0.00399	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Methotrexate—muscle cancer	0.00399	0.00399	CcSEcCtD
Milnacipran—Tachycardia—Etoposide—muscle cancer	0.00398	0.00398	CcSEcCtD
Milnacipran—Abdominal pain—Vincristine—muscle cancer	0.00398	0.00398	CcSEcCtD
Milnacipran—Body temperature increased—Vincristine—muscle cancer	0.00398	0.00398	CcSEcCtD
Milnacipran—Liver function test abnormal—Doxorubicin—muscle cancer	0.00397	0.00397	CcSEcCtD
Milnacipran—Skin disorder—Etoposide—muscle cancer	0.00396	0.00396	CcSEcCtD
Milnacipran—Erectile dysfunction—Methotrexate—muscle cancer	0.00396	0.00396	CcSEcCtD
Milnacipran—Dry skin—Doxorubicin—muscle cancer	0.00395	0.00395	CcSEcCtD
Milnacipran—Hyperhidrosis—Etoposide—muscle cancer	0.00394	0.00394	CcSEcCtD
Milnacipran—Breast disorder—Doxorubicin—muscle cancer	0.00389	0.00389	CcSEcCtD
Milnacipran—Anorexia—Etoposide—muscle cancer	0.00389	0.00389	CcSEcCtD
Milnacipran—Diarrhoea—Dactinomycin—muscle cancer	0.00386	0.00386	CcSEcCtD
Milnacipran—Hypotension—Etoposide—muscle cancer	0.00381	0.00381	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.0038	0.0038	CcSEcCtD
Milnacipran—Abdominal distension—Doxorubicin—muscle cancer	0.00374	0.00374	CcSEcCtD
Milnacipran—Hypersensitivity—Vincristine—muscle cancer	0.00371	0.00371	CcSEcCtD
Milnacipran—Paraesthesia—Etoposide—muscle cancer	0.00366	0.00366	CcSEcCtD
Milnacipran—Haematuria—Methotrexate—muscle cancer	0.00365	0.00365	CcSEcCtD
Milnacipran—Dyspnoea—Etoposide—muscle cancer	0.00364	0.00364	CcSEcCtD
Milnacipran—Somnolence—Etoposide—muscle cancer	0.00363	0.00363	CcSEcCtD
Milnacipran—Angina pectoris—Doxorubicin—muscle cancer	0.00362	0.00362	CcSEcCtD
Milnacipran—Hepatobiliary disease—Methotrexate—muscle cancer	0.00362	0.00362	CcSEcCtD
Milnacipran—Asthenia—Vincristine—muscle cancer	0.00361	0.00361	CcSEcCtD
Milnacipran—Vomiting—Dactinomycin—muscle cancer	0.00358	0.00358	CcSEcCtD
Milnacipran—Rash—Dactinomycin—muscle cancer	0.00355	0.00355	CcSEcCtD
Milnacipran—Decreased appetite—Etoposide—muscle cancer	0.00355	0.00355	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Etoposide—muscle cancer	0.00352	0.00352	CcSEcCtD
Milnacipran—Fatigue—Etoposide—muscle cancer	0.00352	0.00352	CcSEcCtD
Milnacipran—Constipation—Etoposide—muscle cancer	0.00349	0.00349	CcSEcCtD
Milnacipran—Dysuria—Doxorubicin—muscle cancer	0.00348	0.00348	CcSEcCtD
Milnacipran—Neutropenia—Doxorubicin—muscle cancer	0.00348	0.00348	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.00346	0.00346	CcSEcCtD
Milnacipran—Diarrhoea—Vincristine—muscle cancer	0.00344	0.00344	CcSEcCtD
Milnacipran—Hepatitis—Methotrexate—muscle cancer	0.00344	0.00344	CcSEcCtD
Milnacipran—Pollakiuria—Doxorubicin—muscle cancer	0.00344	0.00344	CcSEcCtD
Milnacipran—Urinary tract disorder—Methotrexate—muscle cancer	0.0034	0.0034	CcSEcCtD
Milnacipran—Urethral disorder—Methotrexate—muscle cancer	0.00337	0.00337	CcSEcCtD
Milnacipran—Weight decreased—Doxorubicin—muscle cancer	0.00337	0.00337	CcSEcCtD
Milnacipran—Nausea—Dactinomycin—muscle cancer	0.00335	0.00335	CcSEcCtD
Milnacipran—Gastrointestinal pain—Etoposide—muscle cancer	0.00334	0.00334	CcSEcCtD
Milnacipran—Dizziness—Vincristine—muscle cancer	0.00333	0.00333	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.00329	0.00329	CcSEcCtD
Milnacipran—Erythema multiforme—Methotrexate—muscle cancer	0.00325	0.00325	CcSEcCtD
Milnacipran—Urticaria—Etoposide—muscle cancer	0.00324	0.00324	CcSEcCtD
Milnacipran—Abdominal pain—Etoposide—muscle cancer	0.00322	0.00322	CcSEcCtD
Milnacipran—Body temperature increased—Etoposide—muscle cancer	0.00322	0.00322	CcSEcCtD
Milnacipran—Urinary tract infection—Doxorubicin—muscle cancer	0.00322	0.00322	CcSEcCtD
Milnacipran—Eye disorder—Methotrexate—muscle cancer	0.00321	0.00321	CcSEcCtD
Milnacipran—Vomiting—Vincristine—muscle cancer	0.0032	0.0032	CcSEcCtD
Milnacipran—Cardiac disorder—Methotrexate—muscle cancer	0.00319	0.00319	CcSEcCtD
Milnacipran—Rash—Vincristine—muscle cancer	0.00317	0.00317	CcSEcCtD
Milnacipran—Dermatitis—Vincristine—muscle cancer	0.00317	0.00317	CcSEcCtD
Milnacipran—Haematuria—Doxorubicin—muscle cancer	0.00316	0.00316	CcSEcCtD
Milnacipran—Headache—Vincristine—muscle cancer	0.00315	0.00315	CcSEcCtD
Milnacipran—Hepatobiliary disease—Doxorubicin—muscle cancer	0.00314	0.00314	CcSEcCtD
Milnacipran—Angiopathy—Methotrexate—muscle cancer	0.00312	0.00312	CcSEcCtD
Milnacipran—Mediastinal disorder—Methotrexate—muscle cancer	0.0031	0.0031	CcSEcCtD
Milnacipran—Chills—Methotrexate—muscle cancer	0.00309	0.00309	CcSEcCtD
Milnacipran—Mental disorder—Methotrexate—muscle cancer	0.00301	0.00301	CcSEcCtD
Milnacipran—Hypersensitivity—Etoposide—muscle cancer	0.003	0.003	CcSEcCtD
Milnacipran—Malnutrition—Methotrexate—muscle cancer	0.00299	0.00299	CcSEcCtD
Milnacipran—Nausea—Vincristine—muscle cancer	0.00299	0.00299	CcSEcCtD
Milnacipran—Hepatitis—Doxorubicin—muscle cancer	0.00298	0.00298	CcSEcCtD
Milnacipran—Hypoaesthesia—Doxorubicin—muscle cancer	0.00296	0.00296	CcSEcCtD
Milnacipran—Urinary tract disorder—Doxorubicin—muscle cancer	0.00294	0.00294	CcSEcCtD
Milnacipran—Oedema peripheral—Doxorubicin—muscle cancer	0.00293	0.00293	CcSEcCtD
Milnacipran—Dysgeusia—Methotrexate—muscle cancer	0.00293	0.00293	CcSEcCtD
Milnacipran—Asthenia—Etoposide—muscle cancer	0.00293	0.00293	CcSEcCtD
Milnacipran—Connective tissue disorder—Doxorubicin—muscle cancer	0.00293	0.00293	CcSEcCtD
Milnacipran—Urethral disorder—Doxorubicin—muscle cancer	0.00292	0.00292	CcSEcCtD
Milnacipran—Pruritus—Etoposide—muscle cancer	0.00289	0.00289	CcSEcCtD
Milnacipran—Vision blurred—Methotrexate—muscle cancer	0.00282	0.00282	CcSEcCtD
Milnacipran—Erythema multiforme—Doxorubicin—muscle cancer	0.00282	0.00282	CcSEcCtD
Milnacipran—Diarrhoea—Etoposide—muscle cancer	0.00279	0.00279	CcSEcCtD
Milnacipran—Eye disorder—Doxorubicin—muscle cancer	0.00278	0.00278	CcSEcCtD
Milnacipran—Cardiac disorder—Doxorubicin—muscle cancer	0.00276	0.00276	CcSEcCtD
Milnacipran—Flushing—Doxorubicin—muscle cancer	0.00276	0.00276	CcSEcCtD
Milnacipran—Angiopathy—Doxorubicin—muscle cancer	0.0027	0.0027	CcSEcCtD
Milnacipran—Dizziness—Etoposide—muscle cancer	0.0027	0.0027	CcSEcCtD
Milnacipran—Mediastinal disorder—Doxorubicin—muscle cancer	0.00268	0.00268	CcSEcCtD
Milnacipran—Leukopenia—Methotrexate—muscle cancer	0.00268	0.00268	CcSEcCtD
Milnacipran—Chills—Doxorubicin—muscle cancer	0.00267	0.00267	CcSEcCtD
Milnacipran—Mental disorder—Doxorubicin—muscle cancer	0.00261	0.00261	CcSEcCtD
Milnacipran—Convulsion—Methotrexate—muscle cancer	0.00259	0.00259	CcSEcCtD
Milnacipran—Vomiting—Etoposide—muscle cancer	0.00259	0.00259	CcSEcCtD
Milnacipran—Malnutrition—Doxorubicin—muscle cancer	0.00259	0.00259	CcSEcCtD
Milnacipran—Rash—Etoposide—muscle cancer	0.00257	0.00257	CcSEcCtD
Milnacipran—Dermatitis—Etoposide—muscle cancer	0.00257	0.00257	CcSEcCtD
Milnacipran—Headache—Etoposide—muscle cancer	0.00256	0.00256	CcSEcCtD
Milnacipran—Flatulence—Doxorubicin—muscle cancer	0.00255	0.00255	CcSEcCtD
Milnacipran—Chest pain—Methotrexate—muscle cancer	0.00255	0.00255	CcSEcCtD
Milnacipran—Tension—Doxorubicin—muscle cancer	0.00254	0.00254	CcSEcCtD
Milnacipran—Dysgeusia—Doxorubicin—muscle cancer	0.00254	0.00254	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00253	0.00253	CcSEcCtD
Milnacipran—Vision blurred—Doxorubicin—muscle cancer	0.00244	0.00244	CcSEcCtD
Milnacipran—Infection—Methotrexate—muscle cancer	0.00243	0.00243	CcSEcCtD
Milnacipran—Nausea—Etoposide—muscle cancer	0.00242	0.00242	CcSEcCtD
Milnacipran—Nervous system disorder—Methotrexate—muscle cancer	0.0024	0.0024	CcSEcCtD
Milnacipran—Thrombocytopenia—Methotrexate—muscle cancer	0.00239	0.00239	CcSEcCtD
Milnacipran—Agitation—Doxorubicin—muscle cancer	0.00238	0.00238	CcSEcCtD
Milnacipran—Skin disorder—Methotrexate—muscle cancer	0.00237	0.00237	CcSEcCtD
Milnacipran—Hyperhidrosis—Methotrexate—muscle cancer	0.00236	0.00236	CcSEcCtD
Milnacipran—Anorexia—Methotrexate—muscle cancer	0.00233	0.00233	CcSEcCtD
Milnacipran—Syncope—Doxorubicin—muscle cancer	0.00232	0.00232	CcSEcCtD
Milnacipran—Leukopenia—Doxorubicin—muscle cancer	0.00232	0.00232	CcSEcCtD
Milnacipran—Palpitations—Doxorubicin—muscle cancer	0.00229	0.00229	CcSEcCtD
Milnacipran—Hypotension—Methotrexate—muscle cancer	0.00228	0.00228	CcSEcCtD
Milnacipran—Loss of consciousness—Doxorubicin—muscle cancer	0.00228	0.00228	CcSEcCtD
Milnacipran—Convulsion—Doxorubicin—muscle cancer	0.00225	0.00225	CcSEcCtD
Milnacipran—Hypertension—Doxorubicin—muscle cancer	0.00224	0.00224	CcSEcCtD
Milnacipran—Insomnia—Methotrexate—muscle cancer	0.00221	0.00221	CcSEcCtD
Milnacipran—Chest pain—Doxorubicin—muscle cancer	0.00221	0.00221	CcSEcCtD
Milnacipran—Anxiety—Doxorubicin—muscle cancer	0.0022	0.0022	CcSEcCtD
Milnacipran—Paraesthesia—Methotrexate—muscle cancer	0.00219	0.00219	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00219	0.00219	CcSEcCtD
Milnacipran—Dyspnoea—Methotrexate—muscle cancer	0.00218	0.00218	CcSEcCtD
Milnacipran—Somnolence—Methotrexate—muscle cancer	0.00217	0.00217	CcSEcCtD
Milnacipran—Dry mouth—Doxorubicin—muscle cancer	0.00216	0.00216	CcSEcCtD
Milnacipran—Dyspepsia—Methotrexate—muscle cancer	0.00215	0.00215	CcSEcCtD
Milnacipran—Decreased appetite—Methotrexate—muscle cancer	0.00212	0.00212	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00211	0.00211	CcSEcCtD
Milnacipran—Fatigue—Methotrexate—muscle cancer	0.00211	0.00211	CcSEcCtD
Milnacipran—Infection—Doxorubicin—muscle cancer	0.0021	0.0021	CcSEcCtD
Milnacipran—Shock—Doxorubicin—muscle cancer	0.00208	0.00208	CcSEcCtD
Milnacipran—Nervous system disorder—Doxorubicin—muscle cancer	0.00207	0.00207	CcSEcCtD
Milnacipran—Thrombocytopenia—Doxorubicin—muscle cancer	0.00207	0.00207	CcSEcCtD
Milnacipran—Tachycardia—Doxorubicin—muscle cancer	0.00206	0.00206	CcSEcCtD
Milnacipran—Skin disorder—Doxorubicin—muscle cancer	0.00205	0.00205	CcSEcCtD
Milnacipran—Hyperhidrosis—Doxorubicin—muscle cancer	0.00204	0.00204	CcSEcCtD
Milnacipran—Anorexia—Doxorubicin—muscle cancer	0.00202	0.00202	CcSEcCtD
Milnacipran—Gastrointestinal pain—Methotrexate—muscle cancer	0.002	0.002	CcSEcCtD
Milnacipran—Hypotension—Doxorubicin—muscle cancer	0.00198	0.00198	CcSEcCtD
Milnacipran—Urticaria—Methotrexate—muscle cancer	0.00194	0.00194	CcSEcCtD
Milnacipran—Body temperature increased—Methotrexate—muscle cancer	0.00193	0.00193	CcSEcCtD
Milnacipran—Abdominal pain—Methotrexate—muscle cancer	0.00193	0.00193	CcSEcCtD
Milnacipran—Insomnia—Doxorubicin—muscle cancer	0.00191	0.00191	CcSEcCtD
Milnacipran—Paraesthesia—Doxorubicin—muscle cancer	0.0019	0.0019	CcSEcCtD
Milnacipran—Dyspnoea—Doxorubicin—muscle cancer	0.00189	0.00189	CcSEcCtD
Milnacipran—Somnolence—Doxorubicin—muscle cancer	0.00188	0.00188	CcSEcCtD
Milnacipran—Dyspepsia—Doxorubicin—muscle cancer	0.00186	0.00186	CcSEcCtD
Milnacipran—Decreased appetite—Doxorubicin—muscle cancer	0.00184	0.00184	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00183	0.00183	CcSEcCtD
Milnacipran—Fatigue—Doxorubicin—muscle cancer	0.00182	0.00182	CcSEcCtD
Milnacipran—Constipation—Doxorubicin—muscle cancer	0.00181	0.00181	CcSEcCtD
Milnacipran—Hypersensitivity—Methotrexate—muscle cancer	0.0018	0.0018	CcSEcCtD
Milnacipran—Asthenia—Methotrexate—muscle cancer	0.00175	0.00175	CcSEcCtD
Milnacipran—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00173	0.00173	CcSEcCtD
Milnacipran—Pruritus—Methotrexate—muscle cancer	0.00173	0.00173	CcSEcCtD
Milnacipran—Urticaria—Doxorubicin—muscle cancer	0.00168	0.00168	CcSEcCtD
Milnacipran—Abdominal pain—Doxorubicin—muscle cancer	0.00167	0.00167	CcSEcCtD
Milnacipran—Body temperature increased—Doxorubicin—muscle cancer	0.00167	0.00167	CcSEcCtD
Milnacipran—Diarrhoea—Methotrexate—muscle cancer	0.00167	0.00167	CcSEcCtD
Milnacipran—Dizziness—Methotrexate—muscle cancer	0.00162	0.00162	CcSEcCtD
Milnacipran—Hypersensitivity—Doxorubicin—muscle cancer	0.00156	0.00156	CcSEcCtD
Milnacipran—Vomiting—Methotrexate—muscle cancer	0.00155	0.00155	CcSEcCtD
Milnacipran—Rash—Methotrexate—muscle cancer	0.00154	0.00154	CcSEcCtD
Milnacipran—Dermatitis—Methotrexate—muscle cancer	0.00154	0.00154	CcSEcCtD
Milnacipran—Headache—Methotrexate—muscle cancer	0.00153	0.00153	CcSEcCtD
Milnacipran—Asthenia—Doxorubicin—muscle cancer	0.00152	0.00152	CcSEcCtD
Milnacipran—Pruritus—Doxorubicin—muscle cancer	0.0015	0.0015	CcSEcCtD
Milnacipran—Nausea—Methotrexate—muscle cancer	0.00145	0.00145	CcSEcCtD
Milnacipran—Diarrhoea—Doxorubicin—muscle cancer	0.00145	0.00145	CcSEcCtD
Milnacipran—Dizziness—Doxorubicin—muscle cancer	0.0014	0.0014	CcSEcCtD
Milnacipran—Vomiting—Doxorubicin—muscle cancer	0.00134	0.00134	CcSEcCtD
Milnacipran—Rash—Doxorubicin—muscle cancer	0.00133	0.00133	CcSEcCtD
Milnacipran—Dermatitis—Doxorubicin—muscle cancer	0.00133	0.00133	CcSEcCtD
Milnacipran—Headache—Doxorubicin—muscle cancer	0.00133	0.00133	CcSEcCtD
Milnacipran—Nausea—Doxorubicin—muscle cancer	0.00126	0.00126	CcSEcCtD
